| Bioactivity | WB518 is a potent STAT3 inhibitor. WB518 effectively inhibits STAT3 activation and Keratin 17 expression. WB518 effectively alleviates imiquimod (HY-B0180) and TPA (HY-18739)-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17[1]. |
| Invitro | WB518 (5-25 μM) 通过抑制 STAT3 Tyr705 (Y705) 的磷酸化，显着降低 HaCaT 细胞中角蛋白 17 (K17) 的 mRNA 和蛋白水平[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> WB518 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | WB518 (每个部位 17.5 μg 和 35 μg，外用，每日，持续 5 天)可改善 TPA (HY-18739) 诱导的银屑病样皮肤炎症，显著改善小鼠银屑病模型的表型特征[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C20H16BrN5O5S |
| Molar Mass | 518.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ti C, et al. WB518, a novel STAT3 inhibitor, effectively alleviates IMQ and TPA-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17. Int Immunopharmacol. 2024 Jan 25;127:111344. |